Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement

Iantrek Corporation has announced positive 2-year results from its prospective clinical study of a bio-interventional platform for uveoscleral outflow enhancement in open-angle glaucoma (OAG) patients undergoing combined cataract surgery.

According to the company, results demonstrated the durability of intraocular pressure (IOP) reduction and uveoscleral outflow enhancement provided by Iantrek’s cyclodialysis procedure with bio-reinforcement.

Iantrek initiated pre-commercial launch access to its bio-reinforced cyclodialysis platform for select US centers in 2024 and plans for broader US commercialization in Q3 2025.

Results from the study showed 74% of treated eyes achieved a ≥20% reduction in IOP at 2 years with the same or fewer glaucoma medications. Additionally, mean IOP was reduced by 34% from baseline of 21.9 ± 4.9 mmHg to 13.84 ± 2.42 mmHg and the use of IOP-lowering medications decreased by >60%, from an average of 1.42 ± 1.29 to 0.55 ± 0.52 at 2 years.

Robert N. Weinreb, MD, distinguished professor and chair of ophthalmology at the University of California, San Diego, commented on the results in a press release from the company.

“This study highlights a meaningful advancement in glaucoma surgery by safely and effectively targeting the uveoscleral pathway through a minimally invasive, bio-interventional approach,” said Weinreb. “This represents a groundbreaking, hardware-free solution using next-generation, homologous bio-tissue materials for superior biocompatibility.”

At the end of 2024, Iantrek released 1-year follow-up data from the first 100 eyes enrolled in the CREST Registry, a prospective, real-world observational study assessing the outcomes of bio-interventional procedures for patients with OAG.

References:

1. Iantrek announces positive 2-year results demonstrating efficacy and safety of its bio-interventional technology for uveoscleral outflow enhancement in glaucoma patients. Globe Newswire. Published March 18, 2025. Accessed March 20, 2025. https://www.globenewswire.com/news-release/2025/03/18/3044649/0/en/Iantrek-Announces-Positive-2-Year-Results-Demonstrating-Efficacy-and-Safety-of-Its-Bio-Interventional-Technology-for-Uveoscleral-Outflow-Enhancement-in-Glaucoma-Patients.html